A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
Public ClinicalTrials.gov record NCT00541658. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, & 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis.
Study identification
- NCT ID
- NCT00541658
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Warner Chilcott
- Industry
- Enrollment
- 923 participants
Conditions and interventions
Conditions
Interventions
- risedronate Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2007
- Primary completion
- Mar 31, 2010
- Completion
- Mar 31, 2010
- Last update posted
- Apr 21, 2013
2007 – 2010
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Oakland | California | — | — |
| Research Site | San Diego | California | — | — |
| Research Facility | Walnut Creek | California | — | — |
| Research Site | Walnut Creek | California | — | — |
| Research Site | Lakewood | Colorado | — | — |
| Research Site | Leesburg | Florida | — | — |
| Research Site | Melbourne | Florida | — | — |
| Research Site | South Miami | Florida | — | — |
| Research Site | Gainesville | Georgia | — | — |
| Research Site | Champaign | Illinois | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Bethesda | Maryland | — | — |
| Research Site | Brockton | Massachusetts | — | — |
| Research Site | Omaha | Nebraska | — | — |
| Research Site | Las Vegas | Nevada | — | — |
| Research Site | Greenville | North Carolina | — | — |
| Research Site | Portland | Oregon | — | — |
| Research Site | Seattle | Washington | — | — |
| Research Site | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00541658, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2013 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00541658 live on ClinicalTrials.gov.